The main prognostic factors and why minimal residual disease is becoming crucial in multiple myeloma
The CLL2-BAG trial: can CLL patients safely cease treatment after remission?
The importance of educating stem cell transplant recipients on tuberculosis and cytomegalovirus
Overcoming the shortfalls of ibrutinib with fludarabine in CLL patientss
MOR208: an effective drug for the treatment of CLL